Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum
Date: August 12, 2025
The biopharmaceutical landscape is witnessing significant advancements in the field of cell-based immunotherapy, particularly in the treatment of solid tumors. According to a recent report by DelveInsight, the Tumor-Infiltrating Lymphocyte (TIL) Therapy Market is gaining momentum, driven by expanding oncology applications. This report, released on August 12, 2025, provides a comprehensive analysis of the current treatment practices, addressable patient population, and competitive landscape.
Over the past decade, cell-based immunotherapy has emerged as a promising approach for treating various solid tumors. Companies such as Iovance Biotherapeutics, Obsidian Therapeutics, Biosyngen, KSQ Therapeutics, and others are at the forefront of developing and producing TIL therapies. These therapies are poised to significantly impact and enhance the TIL therapies market.
The DelveInsight report highlights several key takeaways:
Market Size and Forecast: The report provides insights into the current and forecasted market size from 2020 to 2034, segmented into seven major markets (7MM). This segmentation helps in understanding the geographical distribution and potential growth areas for TIL therapies.
Addressable Patient Population: The report identifies top indications for TIL therapies, including melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, head and neck squamous cell carcinoma (HNSCC), colorectal cancer, and other solid tumors. These indications are based on approved therapies and ongoing pipeline activities.
Competitive Landscape: The report offers a detailed understanding of the competitive landscape, including the market share of individual therapies. This information is crucial for stakeholders to assess the positioning and potential of various players in the market.
Precigen, Inc., a biopharmaceutical company specializing in gene and cell therapies, operates within this dynamic sector. Although not explicitly mentioned in the DelveInsight report, Precigen’s focus on immuno-oncology aligns with the broader trends highlighted in the TIL therapies market. The company, based in Germantown, United States, aims to revolutionize healthcare by providing innovative solutions for various health concerns, including oncology.
As of August 10, 2025, Precigen’s stock closed at $1.74, with a 52-week high of $2.17 and a low of $0.65. The company’s market capitalization stands at approximately $504.76 million. Despite a negative price-to-earnings ratio of -2.886, Precigen continues to pursue its mission of developing groundbreaking therapies in the biotechnology sector.
The growing interest and investment in TIL therapies underscore the potential for significant advancements in cancer treatment. As the market evolves, companies like Precigen may find opportunities to leverage their expertise in gene and cell therapies to contribute to this promising field.